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Summary
Ovarian cancer is, with its high incidence and mortality, a worldwide problem. One reason for this is the lack of 
 symptoms. The second reason is practically non-existant screening for ovarian cancer. Until recently, the only routinely 
used marker for ovarian abnormalities was CA125. Determination of HE4 levels, together with those of CA125 and the 
 calculation of the ROMA index, is a suitable method for improving primary detection of ovarian cancer. The measurement 
of serum HE4 is a useful method for diff erential diagnosis between benign gynecologic disease and ovarian cancer.
KEY WORDS: ovarian cancer, CA125, HE4 (Human epidydimis protein), ROMA (Risk of Ovarian Malignancy Algorithm) index.
PREDNOSTI HUMANOG EPIDIDIMALOG PROTEINA (HE4) 
U ODNOSU NA TRADICIONALNO KORIŠTENE TUMORSKE MARKERE U GINEKOLOŠKOJ ONKOLOGIJI
Sažetak
Rak jajnika je globalni javnozdravstveni problem radi visoke učestalosti i smrtnosti. Jedan od razloga za to je nedosta-
tak jasnih kliničkih simptoma bolesti. Drugi razlog je praktički nepostojanje metode probira za rak jajnika. Donedavno, je-
dini rutinski koristan tumorski marker za karcinom jajnika bio je CA125. Određivanje razine HE4, zajedno s CA125 i izračun 
indeksa ROMA pogodna je metoda poboljšanja dijagnostike primarnog otkrivanja raka jajnika. Mjerenje serumskog HE4 
korisno je u razlikovanju benignih ginekoloških bolesti od karcinoma jajnika.
 Ključne riječi: rak jajnika, CEA 125, HE4 (Humani epidimelni protein), ROMA index
INTRODUCTION
Despite the relatively low prevalence, ovari-
an cancer is the six leadingcause of death from 
cancer among women in Croatia. Distribution of 
newcancer cases in 2013 by site was 446/9769 ovar-
ian cancer in females (5%). Incidence rate ovarian 
cancer is 20.1 and it is too high compared to the 
standardized rate of the world population, which 
is 10.8. (1). The most reliable, but not always easy 
approach to diagnose ovarian cancer relies on 
multiple, time-consuming and expensive tools: pel-
vic examination, transvaginal ultrasonography, 
PET-CT and laboratory tests. 
Laboratory tests
A tumor marker is a naturally occurring mol-
ecule that is measured in serum, plasma, or other 
body fl uids or in tissue extracts or paraffi  n-em-
bedded tissues (to identify the presence of cancer) 
to assess patient prognosis or to monitor a patient´s 
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response to therapy with the goal of improving 
the clinical management of the patient. Tumor 
markers are found inside cells, both in the cyto-
plasm and nuclei, and they are associated with 
cell surface membranes. They also circulate in 
blood. The ideal marker for the purpose of diag-
nosis would have two characteristics: it would be 
secreted into the blood in measurable concentra-
tion only after the cells that produce it had under-
gone malignant transformation, and detection of 
it would permit conclusions as to the site of the 
tumor from which it arose. Unfortunately markers 
with close to 100% specifi city (undetectable in be-
nign diseases and healthy individuals) and 100% 
sensitivity (always detectable even in the early 
stages of a tumor) do not exist.
The most common laboratory test is CA125, 
the only ovarian cancer biomarker routinely used 
in clinical practice. In 1981, Bast et al. identifi ed 
the CA125 antigen with the development of the 
OC 125 murine monoclonal antibody against cell 
line OVCA 433, which was derived from a patient 
with ovarian serous carcinoma. This new mucin 
molecule has been designated Ca125/MUC16 
[mucin 16, cell surface associated (MUC16) gene] 
and consists of a 156–amino-acid tandem-repeat 
region in theN-terminus and a possible transmem-
brane region and tyrosine phosphorylation site in 
the C-terminus (2). The fi rst immunoassay for 
CA125, commercialized in 1983. Assays for CA125 
have since been adapted to automated platforms. 
Concentrations of CA125 may vary among manu-
facturers owing to diff erences in calibration, assay 
design, and reagent specifi cities. The lack of an In-
ternational Standard for CA125 decreases prog-
ress in improving between-method comparability 
and manufacturers should specify the standard 
preparation against which their method is calibra-
ted, and laboratories should indicate the CA125 
method used on their clinical reports. It suff ers 
from limited diagnostic performance due to poor 
sensitivity and specifi city. A number of groups in-
cluding the NACB 2008 the European Group on 
Tumor Markers (EGTM) and the National Insti-
tutes of Health (NIH) Consensus Conference have 
published guidelines for optimal use of tumor 
markers in routine clinical practice for screening, 
prevention, diagnosis, and treatment ovarian can-
cer (3,4,5). CA125 is recommended (in combina-
tion with transvaginal ultrasonography) forearly 
detection of ovarian cancer only in women at high 
risk for this disease and for diff erential diagnosis 
of suspicious pelvic masses in postmenopausal 
women. It is also recommended for monitoring 
treatment, prognosis, and disease relapse in pa-
tients with known ovarian cancer. It is not recom-
mended for regular screening or diagnosis (3).
When ovarian cancer is detected at an early 
stage, where the disease is still contained within 
the ovaries (stage I), 5-year survival rates can ap-
proach 90% with optimal surgery and currently 
available combination chemotherapy. By contrast, 
ovarian cancer that has spread throughout the 
peritoneal cavity or outside the abdomen (stages 
III and IV) is associated with 5-year survival of 
less than 30%. In women with epithelial ovarian 
cancer, 80% have CA125 levels >35 kU/L, with el-
evations of 50%–60% in clinically detected stage I 
disease, 90% in stage II, and >90% in stages III and 
IV. Several benign pelvic conditions cause in-
creased CA125. These include endometriosis, be-
nign ovarian cysts, pelvic infl ammatory disease 
and salpingitis, as well as nongynecologic diseas-
es including cirrhosis, ascites, peritoneal infl am-
mation, pleuritis/pericarditis, pancreatitis, renal 
failure, and liver disease. Also CA 125 increased 
during menstrual phase and descreased because 
regular smoking and caff eine consumption (6).
Human epidydimis protein (HE4) was dis-
covered by Kirchhoff  et al in 1991 as a transcript 
exclusively expressed in distal epididymis in men 
(7). The gene, also known as WFDC2 is located on 
human chromosome 20q12-13.1, a region that in-
cludes several genes that encode whey acidic pro-
tein (WAP). Its mature 25-kDa glycosylated form 
consists of a single peptide and two whey acidic 
protein (WAP) domains that contain a ‘four disul-
fi de core’ composed of eight cysteine residues. 
The function HE4 is unknown, but may be func-
tion as an antiproteinase within the male repro-
ductive tract in sperm maturation. Human epi-
dydimis protein (HE4) is glycoprotein overex-
pressed in patients with serous and endometrioid 
epithelial ovarian cancer (8-10). Since HE4 is over-
expressed in ovarian cancers relative to normal 
tissues, 2003. Hellstrom et al examined the poten-
tial of HE4 as a secreted biomarker for ovarian 
cancer in serum. Murine monoclonal antibodies 
2H5 and 3D8 were prepared against HE4 protein 
produced in mammalian cells from an HE4-IgG2a 
Fc fusion construct (11). A heterologous double 
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determinant immunoassay was established with 
the two antibodies that bound to distinct domains 
on the HE4 protein. The fi rst commercially avail-
able assay for serum HE4 was developed as an 
EIA (Fujirebio Diagnostic, Inc., Malvern, PA). To-
day on the market there are many diff erent manu-
facturers of commercial immunoassays (EIA, 
CMIA) to determinate HE4 in serum.
HE4 is a superior biomarker for distinguish-
ing benign from malignant gynecological disease. 
The main challenge for laboratory tumor markers 
of ovarian cancer is to allow the accurate detection 
of malignancy as early as possible to imprive clin-
ical outcome and survival of patients. The diag-
nostic accuracy of HE4 in diff erentiating malig-
nant ovarian tumors from benign gynecological 
conditions was assessed by metaanalysis and 
found to have a pooled sensitivity of 0.74 and a 
pooled specifi city of 0.87. Lin et al. searched the 
MEDLINE, EMBASE, and Cochrane Library data-
bases for studies published up to June 2012 that 
evaluated HE4 accuracy. Meta-analysis was used 
to calculate sensitivity, specifi city, the positive 
likelihood ratio (PLR), the negative likelihood ra-
tio (NLR) and the area under curve (AUC). A total 
of 11 studies with 3395 patients who fulfi lled all 
inclusion criteria were considered in the analysis. 
No publication bias was found. HE4 had a pooled 
sensitivity of 0.74 (95% confi dence interval (CI), 
0.72–0.76) and a pooled specifi city of 0.87 (95% CI, 
0.85–0.89). Overall, the positive likelihood ratio 
was 8.04 (95% CI, 4.89–13.21) and the negative 
likelihood ratio was 0.27 (95% CI, 0.22–0.34). When 
HE4 was combined with CA125, the sensitivity 
was higher than that of HE4 alone at the expense 
of lower specifi city (12). Another meta-analyses in 
2012 included 16 studies, to criticaly revise the 
availabile literature to confi rm clinical value HE4. 
These meta-analyses revealed an ovarall sensitiv-
ity of 79% (95 Cl 76% to 81%) and specifi city of 
93% 95% CI 92% to 94%) for HE4, and an ovarall 
sensitivity of 78% (95% CI 76% to 80%) for CA125. 
Meta-analyses confi rm that the risk for ovarian 
cancer is signifi cantly increased for patients with 
HE4 positive results (OR 37,2), HE4 exhibited a 
signifi cantly higher specifi ty than CA125 (93% vs. 
78%) and HE4 outperforms CA125 in identifying 
ovrian cancer (LR+: 13,0 VS.4,2)(13).
CA 125 is elevated in benign gynecological 
conditions. HE4 is less frequently elevated than 
CA 125 in benign disease (8% vs 29%), improving 
specifi city, particularly in premenopausal wom-
en. In endometriosis, CA 125 was elevated in 67% 
of cases, compared with 3% for HE4. Elevation of 
HE4 can occur in renal failure and in lung cancer 
(14-16).
A combination of CA 125 and HE4 was found 
to be a bett er predictor of malignancy than either 
marker alone. In a study assessing the perfor-
mance of 65 ovarian cancer–related biomarkers 
for evaluation of adnexal masses, the CA 125–HE4 
combination was found to be superior all other 
marker combinations (14). For the evaluation of 
possible malignant disease in women presenting 
with pelvic masses, a combination of CA 125, HE4, 
and age was found to provide a higher diagnostic 
value (area under the curve [AUC] of 0.797) than 
CA 125 alone (AUC of 0.677). This combination 
was also found to have diagnostic relevance in the 
sett ing where there is a need to distinguish endo-
metrial cancer from benign uterine disease, with a 
sensitivity of 60.4% and a specifi city of 100%. Var-
ious factors from malignancy may infl uence se-
rum HE4 levels and should be carefully consid-
ered in interpreting values of HE4. Unlike CA125 
levels, which decrease with age, HE4 levels in-
crease signifi cantly with age. HE4 levels are also 
aff ected by pregnancy: pregnant women have sig-
nifi cantly lowered levels of HE4 in comparison 
with age-matched nonpregnant premenopausal 
women. Older women, women with a later men-
arche, and smokers also had signifi cantly higher 
levels of HE4. Menstrual cycle, endometriosis and 
estrogen and progestin contraceptive usage do 
not alter serum levels of HE4 (17). With a molecu-
lar weight of 25 kD, which is below of the glomer-
ular fi ltration cutoff , HE4 levels have also been 
found to be elevated in chronic kidney disease 
and renal failure.
The ROMA index combines CA125 and HE4 
values along with the menopausal status into a 
predictive index, which in turn is used to calculate 
the predicted probability of ovarian cancer (from 0 
to 100%). The regression formulae are as follows, 
where LN is the natural logarithm (16,17). In pre-
menopausal women Predictive Index (PI) = −12.0 + 
2.38 * LN (HE4) + 0.0626 x * LN (CA-125 In post-
menopausal women Predictive Index (PI) = −8.09 + 
1.04 * LN (HE4) + 0.732 * LN (CA-125 Predicted 
Probability (PP) = exp (PI) [1exp(PI)]. To calculate 
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the ROMA value, insert the calculated value for 
PI into following equation: ROMA value (%) = 
exp(PI) / [1 + exp(PI)] * 100 (18).
Several published studies show that ROMA 
index helps in the triage of pre - and postmeno-
pausal women for ovarian cancer (19,20). Moore et 
al. found that the algorithm correctly classifi ed 
94% of women with epithelial ovarian cancer (18). 
This high accuracy helps to stratify the women 
into low- and high-risk groups and thus may con-
tribute to bett er diagnosis, treatment and out-
come.
Given the obsolescence guidelines dating back 
to 2008, European Group of Tumor Markers 
(EGTM) published 2012. Guidelines for Use of 
Biomarkers in Gynecological Cancer (21).
European Group of Tumor Markers (EGTM) 
conclusions are as follows:
Established tumor markers for ovarian cancer
• In women with epithelial ovarian cancer, ap-
proximately 80% have CA 125 levels > 35kU/L, 
with elevations in 50%-60% in clinical stage I 
disease, 80%-90% in stage II, and > 90% in stage 
III-IV.
• CA 125 is not recommended as a screening test 
in asymptomatic women without a hereditary 
risk outside the context of a clinical trial because 
CA 125 lacks diagnostic sensitivity for stage I 
disease and those with mucinous-type tumors 
and additionally lacks disease specifi city, espe-
cially for premenopausal women.
• CA 125 is advised annually in women with a 
hereditary ovarian cancer syndrome in addition 
to pelvic and ultrasound examination. How-
ever, there is no evidence that screening these 
high-risk women reduces morbidity or mor-
tality.
• CA 125 combined with Ultrasound is recom-
mended in distinguishing benign from malig-
nant disease in women with a pelvic mass, par-
ticularly in postmenopausal women. An algo-
rithm to calculate the risk of malignancy index 
(RMI) has been developed, where CA 125 is in-
corporated with transvaginal ultrasound and 
menopausal status to estimate the probability 
of malignant potential for a pelvic mass in pre-
menopausal and postmenopausal women with 
reported sensitivities of 71%-78 % and specifi ci-
ties of 75%-94 %.
• Concentrations of CA 125 > 95kU/L in post-
menopausal women can discriminate malig-
nant from benign pelvis masses with a positive 
predictive value of 95%.
• Benign conditions resulting in increased CA 
125 levels are a confounding factor in premeno-
pausal women e.g. (pregnancy, endometriosis, 
cysts and uterine leiomyoma).
• CA 125 may be considered for monitoring treat-
ment of ovarian cancer, but there is no consensus 
on how to defi ne a CA 125-based response. It is 
recommended that the marker response should 
be based on a decrement of 50% in concentra-
tions or alternatively be based on a statistical es-
timation of decrements adjusted to both analyti-
cal and biological variation of the marker.
• CA 125 may be of prognostic signifi cance pre-
operatively, postoperatively and during the fi rst 
three courses of primary chemotherapy.
• CA 125 measurements are recommended dur-
ing follow-up. Continuously elevated concen-
trations during follow-up are predictive for tu-
mor growth. To indicate progression either a 
confi rmed doubling of CA 125 levels or an ap-
proach based on analytical and biological varia-
tion may be used.
• Alpha-fetoprotein (AFP) and human chorion-
gonadotropin (HCG) are established markers 
for germ cell tumors both for diagnosis and 
monitoring. Elevated AFP and HCG concentra-
tions > 100 IU/L indicate the presence of non-
dysgerminotous elements.
Potential tumor markers for epithelial ovarian cancer
• Human Epididymis protein (HE4) has been 
proposed as a new tumor marker especially for 
non-mucinous subtypes of epithelial ovarian 
cancer. Initial studies have suggested an in-
creased diagnostic specifi city of HE4 compared 
to CA 125, mainly in premenopausal women. 
The sensitivity of CA 125 and HE4 is suggested 
to be similar.
• Data indicate that HE4 measurement in healthy 
premenopausal women as well as in women 
with endometriosis may be carried out at any 
phase of the menstrual cycle, and irrespective 
of hormonal medication.
• An algorithm, the “Risk of Ovarian Malignancy 
Algorithm” (ROMA) has been suggested to 
evaluate the performance of utilizing the com-
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bination of HE4 and CA 125 to predict the risk 
of serous epithelial ovarian cancer in women 
with pelvic mass. However, the ROMA algo-
rithm should undergo further clinical evalua-
tion before recommending the algorithm in 
clinical use.
• The utility of combing HE4 and CA 125 is un-
clear due to small and selected study popula-
tions. Further prospective studies are needed to 
investigate HE4 before implementing the mark-
er into routine clinical practice.
• CEA and CA 19.9 measurements may be con-
sidered in determining treatment response in 
monitoring of patients with mucinous tumors.
In our laboratory, two years ago, we routine-
ly measure CA 125 and HE4 on Cobas e411 device, 
Roche. Sample material is serum, collected using 
standard sampling tubes with separatinggel, after 
centrifugation of whole blood. Sample volume is 
10 μL for HE4 and 20 μL for CA 125. Test principle 
HE4 is one-step sandwich assay, with measuring 
range 15-1500 pmol/L. CA 125 test is one-step 
sandwich assay with measuring range 0,6-5000 U/
mL. The Elecsys CA 125  tumor marker assay is 
based on the monoclonal M11 and OC125 anti-
bodies. Testing time is 18 min. We also calculated 
ROMA index and stratifi cate into low risk and 
high risk group. The following cut-off  points were 
used in order to provide a specifi city level of 75% 
for the Elecsys HE4 and Elecsys CA125 assay com-
bonation: premenopausal women ROMA value 
≥ 11.4% = High risk of fi nding epithelial ovarian 
cancer; ROMA value <11.4% = Low risk of fi nding 
epithelial ovarian cancer. In group postmeno-
pausal women ROMA value ≥29.9% = High risk of 
fi nding epithelial ovarian cancer ROMA value 
<29.9% = Low risk of fi nding epithelial ovarian 
cancer (22). Also, in case of elevated urea and cre-
atinine issue remark: Impaired kidney function 
can cause falsely elevated HE4.
CONCLUSION
The large challenge for laboratory tumor 
markers of ovarian cancer diagnosis is to allow the 
accurate detection of malignancy as early as pos-
sible to improve clinical outcome and survival of 
patients. Until recently, the only routinely used 
marker for ovarian, and unfortunatelly for the all 
others gynecological disease, was CA125. Deter-
mination of HE4 levels, together with those of 
CA125 and the calculation of the ROMA index, is 
a suitable method for improving primary detec-
tion of ovarian cancer. Combination of HE4 and 
CA125 is useful inassessing the response to treat-
ment: correlation between radiology’s imaging-
techniques and tumor marker results was higher 
than 80%. Combination of HE4 and CA125 are 
useful in follow-up in 89,8% of all patients with 
ovarian carcinoma and in 95% of non-mucinous 
ovarian carcinoma. Combination of both tumor 
markers are recommended because changes in the 
relase patt ern are frequently found with chemo-
therapy (23). The measurement of serum HE4 is a 
useful method for diff erential diagnosis between 
benign gynecologic disease and ovarian cancer. 
From literature data HE4 has also emerged as a 
serum biomarker for lung cancer, pulmonary ad-
enocarcinoma, chronic kidney disease, renal fail-
ure and kidney fi brosis. Each of these conditions 
must be considered when interpreting HE4 levels 
in ovarian cancer. With a molecular weight of 25 
kD, which is below the glomerular fi ltration cut-
off , HE4 levels have also been found to be elevated 
in the urine of ovarian cancer patients compared 
with urine from healthy individuals or controls 
with benign disease. Pretreatment levels of HE4 
have a prognostic value in ovarian cancer patients. 
63,3% of patt ients with positive HE4 before treat-
ment have progression disease in the fi rst fi ve 
years of follow-up.
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